Licensor Materials Sample Clauses

Licensor Materials. “Licensor Materials” means any software, programs, tools, systems, data, or other materials made available by Licensor to Licensee in the course of the performance under this Agreement including, but not limited to, the Software and Documentation, as well as any information, materials or feedback provided by Licensee to Licensor relating to the Software and Documentation.
Sample 1Sample 2
AutoNDA by SimpleDocs
Licensor Materials. 1. All cells lines, culture medium and purification processes used for producing XX-000, XX-000 and AR-301. (This includes commercially viable CHO cell line, the identity of the culture medium formula used for manufacturing, scalable, high yield processes for cGMP manufacturing, and improved stable formulation).
Sample 1
Licensor Materials. The quantities of [***] provided by Licensor to Licensee under this Agreement. SCHEDULE 1.25 Licensor Patent Rights [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] SCHEDULE 5.1.1 List of Countries and Territories
Sample 1
Licensor Materials. 1. All cells lines, culture media and purification processes used for producing AR-101 and AR-301. (This includes commercially viable CHO cell line, scalable, high yield processes for cGMP manufacturing, and improved stable formulation).
Sample 1
Licensor Materials. Compounds Present Inventory: Licensor will provide Merck with the Drug Product vials [**]. The bulk API will be provided to Merck against reimbursement by Merck of the costs which Idera had incurred [**]. Merck will elect in writing within [**] days after Effective Date if and to what extent bulk API shall be transferred to Merck. Such election shall be in [**] gram quantities. [**] Approximately [**] grams bulk API Approximately [**] [**]mg Drug Product vials Follow-On Compounds Licensor will provide Merck with up to [**]mg of each Follow-On Compound at time of transfer to Merck pursuant to Section 3.6, [**] to Merck. IDP Compound # Sequence Modifications [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**]. Schedule 1.38 Licensor Patents Idera Number: Docket # Continuation PCT Nationalization County Title: Status Application Number Application Date Patent /Publication Number Grant Date [**] Confidential materials omitted and filed separately with the Securities and Exchange Commission. A total of 7 pages have been omitted. Schedule 2.3 Initial Technology Transfer Technology Transfer Plan — IMO-2055 & IMO-2125 [**] Schedule 2.4 Manufacturing Technology Transfer Manufacturing Technology Transfer Plan — IMO-2055 & IMO-2125 [**] Schedule 3.3 On-Going Trials Budget Theradex® Study Budget — IDP 2055-200 (NSCLC) — Payment Schedule. [**] Confidential materials omitted and filed separately with the Securities and Exchange Commission. A total of 17 pages have been omitted. Schedule 6.5 Patent Countries [**] Schedule 7.3.1 Idera Press Release Contacts: Idera Pharmaceuticals, Inc. MxxXxxxxxx Biomedical Communications Kxxxx Xxxxxxx Cxxxx Xxxxxx 600-000-0000 500-000-0000 E-mail: kxxxxxxx@xxxxxxxxxxx.xxx E-mail: cxxxxxx@xxxxxxxxx.xxx Idera Pharmaceuticals and Merck KGaA to Collaborate on Development of TLR9 Agonists for Treatment of Cancer Cambridge, MA, December XX, 2007 — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it has entered into a worldwide licensing and collaboration agreement with Merck KGaA of Darmstadt, Germany, for the research, development and commercialization of Idera’s Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer. Under the agreement, Idera has agreed to exclusively license the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. In addition, Idera and Merck KGaA have agreed to engage in a research collaboration t...
Sample 1
Licensor Materials. Licensor agrees to provide Knight from time to time with all marketing and sales materials used by Licensor or its licensees outside the Territory for the Licensed Products, in all cases only to the extent Licensor Controls such materials, and Knight shall [***] to the extent Licensor has the right to grant such right to Knight.
Sample 1
Licensor Materials. Upon Bayer's request, Licensor will use Commercially Reasonable Efforts to assist Bayer in its obtaining from Selexis of Materials necessary for Bayer to have Antibodies Manufactured for it; provided that Bayer shall pay or reimburse Licensor for its reasonable out-of-pocket costs and expenses in providing such assistance.
Sample 1
AutoNDA by SimpleDocs
Licensor Materials 
Sample 1

Related to Licensor Materials

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Licensed Software Computer program(s) provided by Contractor in connection with the Deliverables, subject to Section 14 of this Contract.

  • Third Party Technology The Company makes use of third party technology to collect information required for traffic measurement, research, and analytics. Use of third party technology entails data collection. We therefore would like to inform clients the Company enables third parties to place or read cookies located on the browsers of users entering the Company’s domain. Said third parties may also use web beacons to collect information through advertising located on the Company’s web site. Please note that you may change your browser settings to refuse or disable Local Shared Objects and similar technologies; however, by doing so you may be disabling some of the functionality of Company’s services.

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Other Materials On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as the Agent may reasonably request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof.

  • Know-How The term “

  • Proprietary Materials Each of the Parties shall own its own intellectual property including without limitation all trade secrets, know-how, proprietary data, documents, and written materials in any format. Any materials created exclusively by IPS for the School shall be owned by IPS, and any materials created exclusively by Operator for the School shall be Operator’s proprietary material. The Parties acknowledge and agree that neither has any intellectual property interest or claims in the other Party’s proprietary materials. Notwithstanding the foregoing, materials and work product jointly created by the Parties shall be jointly owned by the Parties and may be used by the individual Party as may be agreed upon by both Parties from time to time.

  • Supply of Materials The following materials will be supplied by the department Name of Materials Rate. Place of delivery 1.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!